Vigil Neuroscience has revealed the first condition that it will target: a rare, genetic neurodegenerative disorder called ALSP, or adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.
The Cambridge, Mass.-based company, which bought the rights to all its current drug candidates from Amgen, also announced a $90 million series B financing round on Wednesday.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
